Previous 10 | Next 10 |
– Company plans to file IND for Ziopharm TCR-T program in Q1 of next year for its Library “hotspot” trial – – Eden BioCell on track for IND filing i n Taiwan for autologus CAR-T clinical trial t...
Details the Incumbent Board’s History of Presiding Over Dismal Governance Practices, Numerous Commercial and Strategic Missteps, and Hundreds of Millions of Dollars in Value Destruction Highlights That Chairman Scott Tarriff has Fostered an Anti-Shareholder Cultur...
[[AAXN]], [[ACLS]], [[ADT]], [[AGO]], [[AIG]], [[AINV]], [[ALRM]], [[ALTR]], [[AMCR]], [[AMH]], [[AMN]], [[ANGI]], [[APPN]], [[ATGE]], [[ATRC]], [[AVLR]], [[AYX]], [[AZPN]], [[BFAM]], [[BGS]], [[BHF]], [[BIGC]], [[BILL]], [[BKNG]], [[BLDP]], [[BMRN]], [[BNFT]], [[CABO]], [[CARG]], [[CDAY]], [...
According to a letter, Ziopharm Oncology ([[ZIOP]] +6.7%) has urged its shareholders to reject an attempt from one of its investors to remove four of its eight board members. The investment firm has put forward three of its own board director nominees.“Given the board’s pas...
Gainers: DBV Technologies (DBVT) +61%, AnPac Bio-Medical Science (ANPC) +16%, Community Health Systems (CYH) +15%, ProPhase Labs (PRPH) +12%, ZIOPHARM Oncology (ZIOP) +10%.Losers: Liquidia Technologies (LQDA) -28%, Jounce Therapeutics (JNCE) -...
Urges Shareholders to Sign and Return Ziopharm’s GREEN Consent Revocation Card Emphasizes that Substantial Board Refr eshment is Already in Process Reiterates Commitment to Implementing Strategy and Delivering Significant Value to S h...
Believes Meaningful and Urgent Change is Needed in Ziopharm’s Boardroom to Unlock Value and Reverse a Five-Year Tailspin That has Resulted in a ~75% Decline in Share Price Highlights that the Company’s Share Price has Plunged ~40% Over the Past Year Alone F...
BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast on Thursday, November 5, at 4:30 pm EDT to provide a corporate update and discuss financial results for the third quarter ended Septembe...
BOSTON, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that it has received a notice, and acknowledges the filing of, a preliminary consent solicitation statement by WaterMill Asset Man...
BOSTON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the 7 th Annual Jefferies Cell Therapy Virtual Summit on Octob...
News, Short Squeeze, Breakout and More Instantly...
ZIOPHARM Oncology Inc Company Name:
ZIOP Stock Symbol:
NASDAQ Market:
ZIOPHARM Oncology Inc Website:
TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patients hunTR® discovered new HLA class I and class II restricted TCRs that recognize d...
TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patients Company to wind down TCR-T Library Phase 1/2 trial and concurrently explore potent...
HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Compan...